FindTrial
Sign In

Determination of the effectiveness of a mouthwash and nasal spray in clinical improvement, decrease in the number of viruses and their prolonged action in patients with Covid-19

Evaluation of the effectiveness of an oral antiseptic and nasal spray in improving the clinical picture, decreasing viral load and its substantivity in patients with Sars-cov-2 - Human Research Ethics Committee of the State University of Londrina

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-8tygcz7
Enrollment
Unknown
Registered
2020-12-01
Start date
2020-11-16
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

viral load

Interventions

A) Control Group (n = 15): use of placebo mouthwash and placebo nasal spray: patient will perform mouthwash / gargle for 1 minute (30 s mouth / 30 s gargle) with 5 mL of the solution, 5 times a day. T
D25.583
D26.255.165.055.291

Sponsors

Universidade Estadual de Londrina
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: volunteers; infected with SARS-CoV-2; both sexes; age between 18 to 70 years; be able to gargle.

Exclusion criteria

Exclusion criteria: more than 7 days after the onset of symptoms; need for mechanical ventilation; intubated patients; admitted to the ICU.

Design outcomes

Primary

MeasureTime frame
It is expected to find a reduction in the SARS-CoV-2 viral load in the naso-oropharyngeal samples through the RT-PCR method in patients who used the products with active ingredient.—

Secondary

MeasureTime frame
It is expected to find clinical improvement in patients who used the products with active and to verify its prolonged action. The clinical improvement will be verified through the Performance Status (PS) performance scale and the substantivity action through the RT-PCR in the samples of the 3 days.—

Countries

Brazil

Contacts

Public ContactBernardo Orcina

Universidade de São Paulo

bernardoforcina@outlook.com+5553984480776

Outcome results

None listed

Source: REBEC (via WHO ICTRP)